首页> 外国专利> Process for the manufacture of a solid pharmaceutical composition for oral administration with 5-chloro-N ({(5-2-oxo-3- 4- (3-oxo-4-morpholinyl) -phenyl -1,3-oxazolidin -5-yl} -methyl) -2-thiophenecarboxamide

Process for the manufacture of a solid pharmaceutical composition for oral administration with 5-chloro-N ({(5-2-oxo-3- 4- (3-oxo-4-morpholinyl) -phenyl -1,3-oxazolidin -5-yl} -methyl) -2-thiophenecarboxamide

机译:用于与5-氯-N({(5-2-oxo-3- [4-(3-oxo-4-吗啉基)-苯基] -1,3-恶唑烷定-5-基}-甲基)-2-噻吩甲酰胺

摘要

Production of solid, orally administered pharmaceutical compositions (A) containing 5-chloro-N-(((5S)-2-oxo-3-(4-(3-oxo-4-morpholinyl)-phenyl)-1,3-oxazolidin-5-yl)-methyl)-2-thiophene-carboxamide (I) in hydrophilized form comprises: (a) preparing granules containing (I) in hydrophilized form by wet granulation; and (b) converting the granules, optionally with suitable additives, into (A). Independent claims are included for: (1) the compositions (A) obtained by the process; and (2) solid, orally administered pharmaceutical compositions (A') containing (I) in hydrophilized form in general. ACTIVITY : Thrombolytic; Anticoagulant; Cardiant; Antianginal; Vasotropic; Cerebroprotective. MECHANISM OF ACTION : Coagulation factor Xa inhibitor.
机译:包含5-氯-N-((((5S)-2-Oxo-3-)(4-(3-Oxo-4-吗啉基)-苯基)-1,3-的固体口服药物组合物(A)的生产亲水化形式的恶唑烷-5-(基)-甲基)-2-噻吩甲酰胺(I)包括:(a)通过湿法制粒制备包含(I)亲水化形式的颗粒; (b)将所述颗粒,任选地与合适的添加剂一起,转化为(A)。包括以下方面的独立权利要求:(1)通过该方法获得的组合物(A); (2)口服的固体药物组合物(A'),其通常含有亲水化形式的(I)。活动:溶栓;抗凝物;卡迪恩抗心绞痛变压性脑保护。作用机理:凝血因子Xa抑制剂。

著录项

  • 公开/公告号ES2300845T5

    专利类型

  • 公开/公告日2017-05-16

    原文格式PDF

  • 申请/专利权人 BAYER INTELLECTUAL PROPERTY GMBH;

    申请/专利号ES20040797879T

  • 发明设计人 BENKE KLAUS;

    申请日2004-11-13

  • 分类号A61K9/20;A61K9/16;A61K31/5377;A61P7/02;

  • 国家 ES

  • 入库时间 2022-08-21 13:35:39

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号